Rallybio Corp Financials
This page shows Rallybio Corp (RLYB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Rallybio Corp has an operating margin of -3853.6%, meaning the company retains $-3854 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -9512.0% the prior year.
Rallybio Corp's revenue surged 34.9% year-over-year to $858K, reflecting rapid business expansion. This strong growth earns a score of 92/100.
Rallybio Corp carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 14.50, Rallybio Corp holds $14.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Rallybio Corp generates a -15.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -93.7% the prior year.
Rallybio Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Rallybio Corp generates $3.32 in operating cash flow (-$29.8M OCF vs -$9.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Rallybio Corp generated $858K in revenue in fiscal year 2025. This represents an increase of 34.9% from the prior year.
Rallybio Corp's EBITDA was -$33.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.4% from the prior year.
Rallybio Corp reported -$9.0M in net income in fiscal year 2025. This represents an increase of 84.5% from the prior year.
Rallybio Corp earned $-1.59 per diluted share (EPS) in fiscal year 2025. This represents an increase of 85.0% from the prior year.
Cash & Balance Sheet
Rallybio Corp held $31.4M in cash against $0 in long-term debt as of fiscal year 2025.
Rallybio Corp had 5M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.
Margins & Returns
Rallybio Corp's operating margin was -3853.6% in fiscal year 2025, reflecting core business profitability. This is up 5658.3 percentage points from the prior year.
Rallybio Corp's net profit margin was -1046.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8037.7 percentage points from the prior year.
Rallybio Corp's ROE was -15.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 78.2 percentage points from the prior year.
Capital Allocation
Rallybio Corp invested $19.6M in research and development in fiscal year 2025. This represents a decrease of 52.8% from the prior year.
RLYB Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $222K+4.7% | $212K0.0% | $212K0.0% | $212K | N/A | $299K0.0% | $299K | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.7M-11.8% | $4.1M-31.8% | $6.1M+6.1% | $5.7M | N/A | $8.2M-36.4% | $12.9M+0.1% | $12.9M |
| SG&A Expenses | $3.0M-0.5% | $3.0M-28.6% | $4.2M+0.9% | $4.2M | N/A | $4.1M-6.0% | $4.4M-36.0% | $6.9M |
| Operating Income | -$6.4M+7.4% | -$6.9M+31.1% | -$10.1M-4.0% | -$9.7M | N/A | -$12.1M+29.2% | -$17.0M+13.9% | -$19.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.9M-136.5% | $16.0M+265.1% | -$9.7M-2.8% | -$9.4M | N/A | -$11.5M+29.4% | -$16.2M+14.7% | -$19.0M |
| EPS (Diluted) | N/A | $0.36+263.6% | $-0.22-4.8% | $-0.21 | N/A | $-0.26+29.7% | $-0.37+21.3% | $-0.47 |
RLYB Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $62.3M-8.0% | $67.7M+32.7% | $51.0M-12.0% | $58.0M-14.9% | $68.1M-13.8% | $79.0M-14.5% | $92.4M-7.0% | $99.4M |
| Current Assets | $61.3M-8.1% | $66.6M+32.6% | $50.3M-12.4% | $57.4M-15.4% | $67.8M-13.3% | $78.2M-14.4% | $91.4M-7.2% | $98.5M |
| Cash & Equivalents | $31.4M-2.3% | $32.1M+240.1% | $9.4M-36.1% | $14.8M+6.3% | $13.9M-45.1% | $25.3M+51.9% | $16.7M-13.6% | $19.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.3M-7.0% | $4.6M-8.2% | $5.0M+28.9% | $3.9M-39.4% | $6.5M-21.2% | $8.2M-34.0% | $12.4M+21.7% | $10.2M |
| Current Liabilities | $4.2M-6.6% | $4.5M-10.3% | $5.0M+28.9% | $3.9M-37.4% | $6.2M-23.8% | $8.2M-32.7% | $12.2M+20.6% | $10.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $58.0M-8.1% | $63.0M+37.1% | $46.0M-15.0% | $54.1M-12.3% | $61.7M-12.9% | $70.8M-11.5% | $80.0M-10.3% | $89.2M |
| Retained Earnings | -$302.0M-2.0% | -$296.1M+5.1% | -$312.2M-3.2% | -$302.5M-3.2% | -$293.0M-3.9% | -$282.0M-4.2% | -$270.5M-6.4% | -$254.3M |
RLYB Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.7M+28.6% | -$6.5M+21.8% | -$8.4M+17.9% | -$10.2M-3.5% | -$9.9M+27.2% | -$13.5M-30.0% | -$10.4M+32.6% | -$15.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $3.9M-86.6% | $29.2M+863.0% | $3.0M-72.6% | $11.1M+804.5% | -$1.6M-107.1% | $22.2M+755.4% | $2.6M-74.7% | $10.3M |
| Financing Cash Flow | $6K | $0-100.0% | $10K | $0-100.0% | $18K+263.6% | -$11K-100.2% | $5.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RLYB Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -2888.3%+378.2pp | -3266.5%+1477.4pp | -4743.9%-182.5pp | -4561.3% | N/A | -4035.5%+1661.9pp | -5697.3% | N/A |
| Net Margin | -2636.0%-10190.8pp | 7554.7%+12131.6pp | -4576.9%-124.5pp | -4452.4% | N/A | -3834.8%+1595.3pp | -5430.1% | N/A |
| Return on Equity | -10.1%-35.5pp | 25.4%+46.5pp | -21.1%-3.7pp | -17.5% | N/A | -16.2%+4.1pp | -20.3%+1.1pp | -21.3% |
| Return on Assets | -9.4%-33.1pp | 23.7%+42.7pp | -19.0%-2.7pp | -16.3% | N/A | -14.5%+3.1pp | -17.6%+1.6pp | -19.1% |
| Current Ratio | 14.50-0.2 | 14.74+4.8 | 9.98-4.7 | 14.68+3.8 | 10.87+1.3 | 9.55+2.0 | 7.52-2.3 | 9.77 |
| Debt-to-Equity | 0.070.0 | 0.07-0.0 | 0.11+0.0 | 0.07-0.0 | 0.10-0.0 | 0.12-0.0 | 0.16+0.0 | 0.11 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Rallybio Corp's annual revenue?
Rallybio Corp (RLYB) reported $858K in total revenue for fiscal year 2025. This represents a 34.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rallybio Corp's revenue growing?
Rallybio Corp (RLYB) revenue grew by 34.9% year-over-year, from $636K to $858K in fiscal year 2025.
Is Rallybio Corp profitable?
No, Rallybio Corp (RLYB) reported a net income of -$9.0M in fiscal year 2025, with a net profit margin of -1046.4%.
What is Rallybio Corp's EBITDA?
Rallybio Corp (RLYB) had EBITDA of -$33.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rallybio Corp's operating margin?
Rallybio Corp (RLYB) had an operating margin of -3853.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Rallybio Corp's net profit margin?
Rallybio Corp (RLYB) had a net profit margin of -1046.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Rallybio Corp's return on equity (ROE)?
Rallybio Corp (RLYB) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rallybio Corp's operating cash flow?
Rallybio Corp (RLYB) generated -$29.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Rallybio Corp's total assets?
Rallybio Corp (RLYB) had $62.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Rallybio Corp spend on research and development?
Rallybio Corp (RLYB) invested $19.6M in research and development during fiscal year 2025.
What is Rallybio Corp's current ratio?
Rallybio Corp (RLYB) had a current ratio of 14.50 as of fiscal year 2025, which is generally considered healthy.
What is Rallybio Corp's debt-to-equity ratio?
Rallybio Corp (RLYB) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rallybio Corp's return on assets (ROA)?
Rallybio Corp (RLYB) had a return on assets of -14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rallybio Corp's cash runway?
Based on fiscal year 2025 data, Rallybio Corp (RLYB) had $31.4M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rallybio Corp's Piotroski F-Score?
Rallybio Corp (RLYB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rallybio Corp's earnings high quality?
Rallybio Corp (RLYB) has an earnings quality ratio of 3.32x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Rallybio Corp?
Rallybio Corp (RLYB) scores 58 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.